• Featured Product
  • KD/KO Validated

SLC22A18 Polyklonaler Antikörper

SLC22A18 Polyklonal Antikörper für WB, IP, ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human, Maus, Ratte

Anwendung

WB, IP, IHC, ELISA

Konjugation

Unkonjugiert

Kat-Nr. : 11646-2-AP

Synonyme

BWR1A, BWSCR1A, HET, IMPT1, ITM, ORCTL 2, ORCTL2, p45 BWR1A, SLC22A18, SLC22A1L, TSSC5



Geprüfte Anwendungen

Erfolgreiche Detektion in WBMaushirngewebe, COLO 320-Zellen
Erfolgreiche IPMaushirngewebe

Empfohlene Verdünnung

AnwendungVerdünnung
Western Blot (WB)WB : 1:1000-1:4000
Immunpräzipitation (IP)IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, check data in validation data gallery

Produktinformation

11646-2-AP bindet in WB, IP, IHC, ELISA SLC22A18 und zeigt Reaktivität mit human, Maus, Ratten

Getestete Reaktivität human, Maus, Ratte
In Publikationen genannte Reaktivitäthuman
Wirt / Isotyp Kaninchen / IgG
Klonalität Polyklonal
Typ Antikörper
Immunogen SLC22A18 fusion protein Ag2245
Vollständiger Name solute carrier family 22, member 18
Berechnetes Molekulargewicht 408 aa, 43 kDa
Beobachtetes Molekulargewicht 40-50 kDa
GenBank-ZugangsnummerBC015571
Gene symbol SLC22A18
Gene ID (NCBI) 5002
Konjugation Unkonjugiert
Form Liquid
Reinigungsmethode Antigen-Affinitätsreinigung
Lagerungspuffer PBS mit 0.02% Natriumazid und 50% Glycerin pH 7.3.
LagerungsbedingungenBei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

SLC22A18 is a member of the family of polyspecific organic-cation transporters that localize at the apical membrane surface of renal proximal tubules. SLC22A18 is expressed at high levels in the kidney, liver, colon and in fetal renal proximal tubules and present at lower levels in heart, brain and lung. Defects in SLC22A18 are associated with breast and lung cancer and are the cause of rhabdomyosarcoma type 1, a malignant tumor derived from striated muscle. More recently, SLC22A18 has been shown to functions as a tumor suppressor in glioma and represents a candidate biomarker for long-term survival in this disease.

Protokolle

Produktspezifische Protokolle
WB protocol for SLC22A18 antibody 11646-2-APProtokoll herunterladen
IP protocol for SLC22A18 antibody 11646-2-APProtokoll herunterladen
Standard-Protokolle
Klicken Sie hier, um unsere Standardprotokolle anzuzeigen

Publikationen

SpeciesApplicationTitle
humanWB

Int J Biol Macromol

microRNA-137 functions as a tumor suppressor in human non-small cell lung cancer by targeting SLC22A18.

Authors - Bicheng Zhang
  • KD Validated

Hum Mol Genet

Parent-of-origin tumorigenesis is mediated by an essential imprinted modifier in SDHD-linked paragangliomas: SLC22A18 and CDKN1C are candidate tumor modifiers.

Authors - Attje S Hoekstra
humanIHC

Cancer Epidemiol

Low expression of SLC22A18 predicts poor survival outcome in patients with breast cancer after surgery.

Authors - He Hongyu H